Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Evommune Inc.
Headquarters: Palo Alto, CA, United States of America
Website: https://www.evommune.com/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | May 30, 2024
Finance
Venture Report: Canadian VC Amplitude closes new fund; CinRx’s series C
Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Mar 26, 2024
Deals
Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior
Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Dec 19, 2023
Deals
Dec. 18 Quick Takes: Illumina to divest Grail
Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint
BioCentury | Jul 14, 2023
Finance
July 13 Quick Takes: Apogee prices $300M IPO
Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia
BioCentury | Apr 27, 2023
Emerging Company Profile
Evommune: advancing ex-Dermira assets, screening for new programs using human tissue
Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs
BioCentury | Dec 1, 2022
Finance
With second asset nearing clinic, Escient to test new mast cell targets with $120M series C
Newly backed by NEA, Abingworth and Forge, the biotech is advancing a MRGPRX2 program for urticaria behind its clinical asset for pruritus
BioCentury | Mar 23, 2022
Management Tracks
Sandrock becomes CEO at Voyager
Plus Faga replaces Suria as Anaptys CEO and updates from Mozart, Longboard, Capsida, Phathom and more
Items per page:
1 - 10 of 13